Cerevance, a company focused on the development of precision treatments for central nervous system (CNS) disorders, announced an initial closing of its Series B-1 Extension financing round that will add $47 million to the $51 million previously raised for a total of $98 million. This impressive financing round will support the upcoming Phase 3 clinical trial for CVN424, a first-in-class non-dopamine therapy for patients with Parkinson’s disease, as well as the advancement of a pipeline of novel treatments for other CNS disorders, including Alzheimer’s disease, Amyotrophic lateral sclerosis, and frontotemporal dementia.
Read the full press release here and visit the Cerevance website to learn more.
Press
